Physician profile
Jay H Garten
NPI 1831189950
$13,434.45
in general payments reported to CMS, 2019-2025
38 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,163 · 2020: $920 · 2021: $2,206 · 2022: $1,823 · 2023: $2,391 · 2024: $1,957 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,270 · Consulting Fee: $42.00 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,270.32 |
| Consulting Fee | $42.00 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,695.32 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,573.40 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $843.02 | 2019-2025 | Tremfya, Stelara, Remicade |
| Janssen Scientific Affairs, LLC | $733.78 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $719.12 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Intercept Pharmaceuticals, INC. | $610.90 | 2019-2024 | Ocaliva |
| Gilead Sciences, INC. | $479.89 | 2019-2025 | Epclusa, Livdelzi |
| Genzyme Corporation | $455.57 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $351.06 | 2022-2024 | Dupixent |
| Pfizer INC. | $290.67 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $276.91 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $260.18 | 2019-2023 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $231.95 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $226.13 | 2023-2024 | Ibsrela |
| Lilly USA, LLC | $221.36 | 2023-2025 | Omvoh, Zepbound |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $180.34 | 2024-2025 | Zenpep |
| Celgene Corporation | $179.51 | 2021-2024 | Zeposia |
| Medtronic USA, INC. | $148.19 | 2019 | |
| Enterra Medical, INC. | $140.86 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $129.24 | 2024-2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $109.77 | 2025 | Terlivaz |
| Dova Pharmaceuticals | $95.71 | 2019 | |
| Ironwood Pharmaceuticals, INC | $84.71 | 2019-2023 | Linzess |
| Redhill Biopharma INC. | $80.04 | 2020-2022 | |
| Sentynl Therapeutics, INC. | $42.00 | 2024 | |
| Organon LLC | $41.04 | 2023 | Hadlima, Renflexis |
| Qol Medical, LLC | $38.94 | 2019-2024 | Sucraid |
| Braintree Laboratories, INC. | $26.12 | 2021 | |
| Novo Nordisk INC | $25.66 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $18.28 | 2025 | Rezdiffra |
| Alfasigma USA, INC. | $18.21 | 2020 | |
| Vivus LLC | $17.20 | 2022 | |
| Ethicon US, LLC | $16.78 | 2021 | |
| Shire North American Group INC | $16.48 | 2019 | |
| Fresenius Kabi USA, LLC | $15.38 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.24 | 2023 | |
| Ucb, INC. | $15.01 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Garten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.